Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Cancer Res. 2012 May 30;72(15):3744–3752. doi: 10.1158/0008-5472.CAN-11-2695

Figure 2. The Polar Lipid Fraction of Ascites inhibits NKT cell activation.

Figure 2

The polar lipid fraction was isolated from the ascites of ovarian cancer patients. LCD1dwt cells were treated with ascites or the polar lipid fraction of the ascites for 4 h, then washed extensively and cocultured with a panel of NKT cell hybridomas. (A) IL-2 production was measured as an indication of NKT cell activation. Data are shown as mean ±S.E.M. In addition, treatment with the polar lipid fraction significantly inhibited all hybridomas examined (p<0.001). (B) GM-CSF production was measured as an indication of NKT cell activation. Data shown as mean ±S.E.M. (C) TLC of the Polar Lipid Fraction. The extracted lipids were analyzed by TLC. Gangliosides were detected with a resorcinol–HCl Cu2+ reagent. Bovine brain gangliosides were used as standards as indicated at the left. Tumor gangliosides typically appear as doublets due to heterogeneity in their ceramide lipid moieties.